Type of Mesothelioma:
[The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma – An Expert Consensus Paper]
Pneumologie 2021 May 4 [Link] C Aigner, T Brüning, W E E Eberhardt, M Härter, H-P Kaelberlah, M Metzenmacher, R Shah, C Taube, M Thomas Abstract Asbestos-related mesotheliomas belong to the group of the most frequent occupational diseases in Germany, reaching about 1,000 new cases per year. The disease has a dismal prognosis because most…
Read MoreSarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases
International Journal of Surgical Pathology 2021 May 3 [Link] Diana M Oramas, Michael Zaleski, Cesar A Moran Abstract Sixty-four cases of sarcomatoid pleural mesothelioma represent the basis of this study. The patients are 51 men and 13 women between the ages of 42 and 79 years, who presented with symptoms of chest pain, cough, and…
Read MoreMesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Biomedicines 2021 April 7 [Link] Sören Weidemann, Pauline Gagelmann, Natalia Gorbokon, Maximilian Lennartz, Anne Menz, Andreas M Luebke, Martina Kluth, Claudia Hube-Magg, Niclas C Blessin, Christoph Fraune, Katharina Möller, Christian Bernreuther, Patrick Lebok, Till S Clauditz, Frank Jacobsen, Jakob R Izbicki, Kristina Jansen, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Sarah Minner, Eike Burandt,…
Read MoreInhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids
International Journal of Molecular Sciences 2021 April 22 [Link] Silvia Mola, Giulia Pinton, Marco Erreni, Marco Corazzari, Marco De Andrea, Ambra A Grolla, Veronica Martini, Laura Moro, Chiara Porta Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with a long latency period and dismal prognosis. Recently, tazemetostat (EPZ-6438), an inhibitor of the histone…
Read MoreUnusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series
Surgical Oncology 2020 June [Link] Paul H Sugarbaker, O Anthony Stuart Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Methods:…
Read MoreThree Decades of Malignant Pleural Mesothelioma: An Academic Center Experience
Clinical Lung Cancer 2021 March 27 [Link] Abdullah Nasser, Andrew Baird, Mathieu D Saint-Pierre, Kayvan Amjadi, Scott Laurie, Paul Wheatley-Price Abstract Background: Malignant pleural mesothelioma (MPM) remains a challenging disease to manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based chemotherapy, and indwelling pleural catheters were introduced to MPM care with variable levels of…
Read MoreA nontoxic dose of chrysotile can malignantly transform Met-5A cells, in which microRNA-28 has inhibitory effects
Journal of Applied Toxicology 2021 April 22 [Link] Fangfang Zhang, Xiuyuan Yuan, Hongjing Sun, Xianhong Yin, Yanan Gao, Min Zhang, Zhenyu Jia, Min Yu, Shibo Ying, Hailing Xia, Li Ju, Yun Xiao, He Tao, Jianlin Lou, Lijin Zhu Abstract Chrysotile, which is classified as a class I carcinogen by the International Agency for Research on…
Read More[BRIC-59 study: first results and considerations on the pathway on the access to health care for malignant pleural mesotheliomas]
Epidemiologia e Prevenzione Jan-Apr 2021 [Link] Elisabetta Chellini, Martina Donzellini, Sara Ricciardi, Lucia Kundisova, Lucia Giovannetti, Francesca Battisti, Martina Giusti, Barbara Dallarti, Carolina Mensi Abstract Objectives: to define the most frequent health pathways of cases affected by malignant pleural mesothelioma according to those suggested and evaluated by the most recent specific guidelines. Design: epidemiological descriptive…
Read MoreTranscriptomic alterations in malignant pleural mesothelioma cells in response to long‑term treatment with bullfrog sialic acid‑binding lectin
Molecular Medicine Reports 2021 June [Link] Takeo Tatsuta, Arisu Nakasato, Shigeki Sugawara, Masahiro Hosono Abstract Malignant pleural mesothelioma (MPM) is a universally lethal type of cancer that is increasing in incidence worldwide; therefore, the development of new drugs for MPM is an urgent task. Bullfrog sialic acid‑binding lectin (cSBL) is a multifunctional protein that has…
Read MoreMalignant pleural mesothelioma co-opts BCL-X L and autophagy to escape apoptosis
Cell Death & Disease 2021 April 15 [Link] Duo Xu, Shun-Qing Liang, Zhang Yang, Haitang Yang, Rémy Bruggmann, Simone Oberhaensli, Sabina Berezowska, Thomas M Marti, Sean R R Hall, Patrick Dorn, Gregor J Kocher, Ralph A Schmid, Ren-Wang Peng Abstract Escape from programmed cell death is a hallmark of cancer. In this study, we investigated…
Read More